CLINICAL TRIALS PROFILE FOR ONSOLIS
✉ Email this page to a colleague
All Clinical Trials for ONSOLIS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00293033 ↗ | Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects | Completed | BioDelivery Sciences International | Phase 3 | 2006-02-01 | The purpose of this study is to evaluate the efficacy of BEMA Fentanyl (Onsolis) at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption. |
| NCT00696137 ↗ | Long-term Extension Study of BEMA™ Fentanyl | Completed | BioDelivery Sciences International | Phase 3 | 2008-06-01 | This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain. |
| NCT01158820 ↗ | Alternative Sedation During Bronchoscopy | Completed | Hospira, Inc. | Phase 4 | 2010-06-01 | This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure. |
| NCT01158820 ↗ | Alternative Sedation During Bronchoscopy | Completed | Hospira, now a wholly owned subsidiary of Pfizer | Phase 4 | 2010-06-01 | This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure. |
| NCT01158820 ↗ | Alternative Sedation During Bronchoscopy | Completed | University of Pennsylvania | Phase 4 | 2010-06-01 | This protocol hopes to determine whether the use of dexmedetomidine-ketamine can reduce the use of standard of care fentanyl-midazolam sedation during bronchoscopy. This may result in less respiratory depression while providing better compliance with the procedure. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ONSOLIS
Condition Name
Clinical Trial Locations for ONSOLIS
Trials by Country
Clinical Trial Progress for ONSOLIS
Clinical Trial Phase
Clinical Trial Sponsors for ONSOLIS
Sponsor Name
